ArticleBrain & spine2025
Stereotactic Gamma Knife Radiosurgery for Merkel cell carcinoma brain metastases: case report and systematic review of literature.
Article in Brain & spine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine skin malignancy with an increasing incidence. Although it frequently presents with loco-regional metastases, brain metastases (BMs) are exceptionally rare, lacking standardized treatment protocols. Case description: This report details the case of a 75-year-old male diagnosed with MCC following surgical excision of an inguinal mass, with subsequent adjuvant radiotherapy. Four months post-surgery, imaging revealed a pancreatic nodule and two cerebral lesions. The patient underwent Gamma Knife® stereotactic radiosurgery (GK-SRS) followed by adjuvant immunotherapy with avelumab. MRI follow-ups showed a significant reduction of the cerebellar lesion and full remission of the frontal lesion, with stable remission noted at one year. The patient remained asymptomatic and continued immunotherapy without neurological deficits. Discussion and conclusion: A systematic review conducted in parallel included 17 papers representing 20 patients with MCC BMs. Treatment strategies varied, including surgery, radiotherapy, and SRS, sometimes combined with immunotherapy. Analysis revealed that SRS provided high rates of local control, highlighting its value as a primary treatment option. Surgical interventions were typically reserved for symptomatic cases or diagnostic uncertainty. Cases involving leptomeningeal spread correlated with poor outcomes, particularly when not coupled with immunotherapy. The results of analysis support the efficacy of SRS in managing MCC brain metastases, recommending its use as a first-line option when feasible. Immunotherapy appears to enhance disease control, especially in preventing leptomeningeal complications. These data suggest to incorporate radiosurgery and immunotherapy into treatment paradigms for improving prognosis in MCC patients with brain metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.